966 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
21 Not yet recruiting Oral THU-Decitabine + Nivolumab for Advanced Non-Small Cell Lung Cancer
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Nivolumab;   Drug: Oral THU;   Drug: Decitabine
22 Recruiting Transcutaneous Electrical Acupoint Stimulation for Non-small Cell Lung Cancer Patients
Conditions: Non-Small Cell Lung Cancer;   Lung Cancer
Interventions: Device: TEAS;   Drug: Sanguisorba officinalis L.
23 Not yet recruiting A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Biological: AGS-003-LNG;   Drug: Carboplatin;   Drug: Abraxane;   Drug: Alimta;   Drug: Cisplatin;   Drug: Taxol;   Radiation: Radiation Therapy
24 Not yet recruiting A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Conditions: Non Small Cell Lung Cancer;   Advanced Triple Negative Breast Cancer;   Small Cell Lung Cancer;   Urothelial Cancer;   Mesothelioma;   Malignant Melanoma
Interventions: Drug: Pembrolizumab;   Biological: CDX-1401;   Biological: Poly-ICLC
25 Not yet recruiting Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)
Conditions: Non Small Cell Lung Cancer;   EGFR-TKI Resistant Mutation;   EGFR-TKI Sensitizing Mutation
26 Not yet recruiting Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer
Condition: Non-Small-Cell Lung Cancer
Intervention: Biological: Nivolumab (Opdivo)+Ipilimumab (Yervoy)
27 Not yet recruiting Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK
Condition: Non-Small Cell Lung Cancer
Intervention: Other: No intervention
28 Not yet recruiting Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Conditions: Small Cell Lung Carcinoma;   Carcinoma, Squamous Cell of Head and Neck;   Stomach Neoplasms;   Triple Negative Breast Neoplasms;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms;   Esophagogastric Junction Neoplasms
Interventions: Drug: paclitaxel + carboplatin;   Drug: carboplatin + etoposide;   Drug: gemcitabine + carboplatin;   Drug: nab-paclitaxel (paclitaxel-albumin) + carboplatin;   Drug: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);   Biological: durvalumab;   Biological: tremelimumab
29 Not yet recruiting A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
Condition: Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Pembrolizumab;   Radiation: Single Fraction Radiation Therapy
30 Recruiting A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer
Condition: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Atezolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Pemetrexed
31 Recruiting Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Conditions: Non-Small Cell Lung Cancer;   Malignant Melanoma;   Renal Cell Cancer;   Triple Negative Breast Cancer;   Prostate Cancer;   Head and Neck Cancer;   Colorectal Cancer;   Bladder Cancer
Interventions: Drug: CPI-444;   Drug: CPI-444 + atezolizumab
32 Not yet recruiting Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
Conditions: Carcinoma, Non-Small-Cell Lung;   Brain Neoplasms
Interventions: Drug: Bevacizumab plus erlotinib;   Drug: Erlotinib
33 Recruiting Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: OSE2101;   Drug: Docetaxel;   Drug: Pemetrexed
34 Not yet recruiting Electromagnetic Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the Sampling of Peripheral Lung Nodules
Conditions: Early-stage Lung Cancer;   Non-small Cell Lung Cancer
Interventions: Procedure: Electromagnetic Navigation Bronchoscopy;   Procedure: Transthoracic Needle Biopsy
35 Not yet recruiting D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Biological: D-CIK
36 Not yet recruiting Spleen Radiotherapy Decreases Severe CIT in Advanced NSCLC
Condition: Chemotherapy in Non-Small Cell Lung Cancer
Intervention: Radiation: spleen radiation
37 Not yet recruiting TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Conditions: Adult Solid Neoplasm;   Colorectal Adenocarcinoma;   Metastatic Pancreatic Adenocarcinoma;   Recurrent Breast Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Melanoma of the Skin;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Colorectal Cancer;   Stage IVA Pancreatic Cancer;   Stage IVB Colorectal Cancer;   Stage IVB Pancreatic Cancer
Interventions: Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Pegfilgrastim;   Drug: TLR8 Agonist VTX-2337
38 Not yet recruiting LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
Conditions: Small Cell Lung Cancer;   Ovarian Cancer
Interventions: Drug: LCL161;   Drug: Topotecan
39 Not yet recruiting The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring
Condition: Non-small-cell Lung Carcinoma
40 Recruiting Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Conditions: Advanced Solid Tumors;   Endometrial Cancer;   Melanoma;   Microsatellite Unstable (MSI) Colorectal Cancer;   MMR-deficient Tumors;   Non-small Cell Lung Cancer;   Renal Cell Carcinoma;   Head and Neck Squamous Cell Carcinoma;   Triple Negative Breast Cancer;   Transitional Cell Carcinoma of the Genitourinary Tract
Interventions: Drug: Pembrolizumab;   Drug: INCB039110;   Drug: INCB050465

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years